Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05825950 · ClinicalTrials.gov registry record
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 2
- Study locations
NCT05825950: Recruiting study of Non-muscle Invasive Bladder Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT05825950 is a study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 600 participants, above the 207-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (190% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05825950, a study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer patients.
Primary Outcome
Recurrence free survival (RFS) is measured as the time from start of clinical treatment / study enrollment to the date of first procedure confirming histopathological recurrence, disease progression or death as a first event from any cause during surveillance cystoscopy at 3 months.
Conditions Studied
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2026-09 |
What NCT05825950 shows while recruiting
NCT05825950 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 207-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (190% higher).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05825950 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05825950 about?
NCT05825950 is a clinical study titled "Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)". This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer ...
What is the current status of trial NCT05825950?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-01-25. Estimated completion is 2026-09.
What conditions does trial NCT05825950 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
Who is sponsoring clinical trial NCT05825950?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05825950 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05825950's enrollment target sits among peer trials
600 3rd of 30 higher than 28 of 30 other Non-muscle Invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI